Rationale and Design of NEUTRALIZE-AKI: A Multicenter, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury Requiring Continuous Kidney Replacement Therapy

• Published in: Nephron (2015) Vol. 148; no. 1; p. 43
• Main Authors: Yessayan, Lenar, Humes, H David, Scribe, Emily C, Iyer, Sai Prasad N, Chung, Kevin K
• Format: Journal Article
• Language: English
• Published: Switzerland 01-01-2024
• Subjects: Acute Kidney Injury - etiology; Adolescent; Adult; Aged; Aged, 80 and over; Critical Care; Critical Illness - therapy; Humans; Intensive Care Units; Middle Aged; Renal Dialysis - adverse effects; Renal Replacement Therapy; Treatment Outcome; Young Adult; Selective cytopheretic device; Immunomodulation; Leukocyte; Acute kidney injury; Neutrophils; Effector cells; Innate immunity; Continuous kidney replacement therapy; Inflammation; Cytokine storm; Kidney; Hyperinflammation; Monocytes; Cell-directed extracorporeal therapy
• ISSN: 2235-3186
• DOI: 10.1159/000531880

NEUTRALIZE-AKI is a pivotal study to evaluate the safety and effectiveness of the selective cytopheretic device (SCD) in adult patients with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).
This is a two-arm, randomized, open-label, controlled multi-center pivotal US study which will enroll 200 adult patients (age 18-80 years) in the intensive care unit with acute kidney injury requiring CKRT and at least one additional organ failure across 30 clinical centers. Eligible patients will be randomized to CKRT plus SCD therapy versus CKRT alone. Therapy will be administered for up to 10 days, with the hypothesis that the CKRT plus SCD group will demonstrate a lower mortality rate or better rate of renal recovery than the CKRT alone group by day 90. The primary outcome is a composite of dialysis dependence or all-cause mortality at day 90.
The SCD is a cell-directed extracorporeal therapy that targets and deactivates pro-inflammatory neutrophils and monocytes, with evidence of efficacy across a variety of critically ill patient populations. Knowledge and experience from many of those studies and other AKI trials were incorporated into the design of this pivotal study, with the aim to investigate the role of effector cell immunomodulation in the intervention of AKI.